Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again

Executive Summary

Juno stressed structural differences, safety record and potential of its JCAR017 CAR-T therapy during a Nov. 23 call about the disappointing hold on its ROCKET ALL study for JCAR015 – the second clinical hold for the company’s most advanced development program.

Advertisement

Related Content

Too Sick For CAR-T? Kite Reports Cerebral Edema Death
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
New Interim CAR-T Data Support Kite’s BLA Submission Plans
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097731

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel